Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 7th Annual congress on Probiotics, Nutrition and Microbes
Venue : Panorama Hotel Prague, Milevska 7, 140 63 Praha 4, Czech Republic.

Day 1 :

Probiotics 2018 International Conference Keynote Speaker Maurilia Rojas-Contreras  photo
Biography:

Maurilia Rojas Contreras is a PhD in microbiology from the University of Gothenburg, Sweden. She is a research professor at Universidad Autonoma de Baja California Sur, Mexico since 1997. She has published in international journals regardless lactic acid bacteria, Lactobacillus adhesion to mucus, and probiotics for aquaculture. The main scientific question to answer is to understand the mechanism by which probiotic bacteria benefits your host.Maurilia Rojas Contreras is a PhD in microbiology from the University of Gothenburg, Sweden. She is a research professor at Universidad Autonoma de Baja California Sur, Mexico since 1997. She has published in international journals regardless lactic acid bacteria, Lactobacillus adhesion to mucus, and probiotics for aquaculture. The main scientific question to answer is to understand the mechanism by which probiotic bacteria benefits your host.

 

Abstract:

Abstract 

Statement of the Problem: Arid and semi-arid regions represent one third of the total area of the world including Australia, the southwest of the United States and northwest of Mexico. Probiotics able to survive in these conditions are important to maintain the health of humans and animals inhabiting the isolated arid coasts. Lactic acid bacteria (LAB) include strains from different genera that colonize mammals, birds, and marine animals and are broadly used as probiotic. The aim of this research was to perform a screening and selection of LAB with probiotic potential from faces and intestinal mucus of humans and organisms important for aquaculture and animal production in the northwest of Mexico, an arid coast. Methodology & Theoretical Orientation: Fecal and gastrointestinal mucus samples were collected of at least 10 subjects of humans, piglets, goats, calves, fish, shrimps, oysters and sea cucumber. Viable counts of LAB were performed and predominant bacteria were isolated and assayed for their ability to adhere gastrointestinal mucus from the respective host. Adhering bacteria were genetically identified by 16S rDNA sequence analysis. Findings: Results of viable counts showed an average of 7.0 and 4.0 log CFU/g of LAB in land and marine animals respectively. Isolates of predominant LAB in all species resulted in 1,031strains and 59% of them presented the ability to bind gastrointestinal mucus. LAB with high ability to bind mucus and more frequently isolated were Lactobacillus fermentum, L. Plantarum, Enterococcus faecium, L. Reuteri and L. Salivarius. Conclusion & Significance: These results indicated a rich source of potential probiotics that resist adverse environmental conditions and colonize the intestinal tract of organisms inhabiting isolated arid coasts.

 

 

 

Probiotics 2018 International Conference Keynote Speaker Attila Kiss  photo
Biography:

Attila Kiss is a Professor of food chemistry. He is the Director of Institute Food Science Innovation Centre at Kaposvár University, Hungary. He obtained various experiences as the leader of the Food Science Research Institute of the National Agricultural Research and Innovation Centre’s Institute for Food Sciences, as well as the EGERFOOD Regional Knowledge Centre at Eszterházy Károly College. The scientific topics of his interest are development of functional foodstuffs of health-promoting effects, assessment of bioactive substances, food chemistry, transformation processes of food bioactive components and food safety issues. His impact factor is 71,7. Delivers regularly talks on Hungarian and international conferences (272 times).

 

Abstract:

Propolis is a natural product deriving from plant resins collected by honeybees. Propolis has been applied in the traditional medicine since ancient times, and at present gains growing popularity in healthy foods owing to its beneficial composition and plausible antimicrobial character. In this paper the antimicrobial properties of four different Hungarian propolis samples and their extracts were examined. We investigated the effects of various Hungarian propolis samples on a model microbiota of the large intestine. Until recently, only very few data was published about the impact of propolis on intestinal bacteria.

Agar diffusion test was applied to assess the inhibition zones in order to evaluate the impact of propolis samples on various bacteria strains. Influence of digestion on the antimicrobial activity was assessed by means of an improved in vitro model system simulating the digestion process by a three-step procedure.

Most of the investigated propolis samples exhibited inhibitory activity against the tested bacteria subsequent to the simulated digestion procedure, so digestion appears to have no decisive influence on the antibacterial properties of propolis. Some specific bacterial strains did not prove to be susceptible to propolis in certain concentrations.

Depending on the propolis concentration, the tested bacterial strains proved to be sensitive against the propolis samples of different geographical origin, except for E. coli. The largest inhibition zones were noticed for propolis denoted as “Z” and “B”, followed by “D” and “E” samples. Additionally the Gram negative Bacteroides fragilis showed susceptibility against bee glue. The soluble part of digested propolis samples did not inhibit the growth of E. coli strain, but at the same time it showed activity against all the other tested bacteria. Enterococcus faecium and E. coli displayed resistance against the insoluble part of the digested propolis, whereas the other investigated 10 bacteria exhibited sensitivity.

Based on our results it might be stated that the actual biological impact of propolis samples of diverse origin can just be accurately estimated if well-tailored model studies are performed on representative human intestinal bacteria. On the basis of the current knowledge, in this paper we pointed out the prospects of applicability of selected propolis samples for manufacturing functional foodstuffs of beneficial physiological features in the future.

 

Keynote Forum

Shriniwas Narsingrao Gujjarwar

Shri Krishna Govt. Ayurved College, Haryana

Keynote: Specialised treatment methods in Ayurveda as Probiotic

Time : 10:55-11:35

Probiotics 2018 International Conference Keynote Speaker Shriniwas Narsingrao Gujjarwar photo
Biography:

Dr. Shriniwas Gujjarwar is working as Professor and Head of Dept. of Shalyatantra (Surgery) under department of AYUSH, Govt. of  Haryana at shri Krishna Govt. Ayurved College, Kurukshetra, Haryana. He is having 20 years of Academic and Clinical experience in the field of Ayurveda. He has completed his graduation and post graduation in Ayurveda from Dr. Babasaheb Ambedkar University, Aurangabad, Maharastra state with specialization in Shalyatantra. He is having vast knowledge and experience in academic and clinical field and is working as incharge to various academic committees and as a member to various committees constituted by the Govt.of Haryana and CCIM, AYUSH Ministry Govt. Of India. He has presented lectures on various topics as Guest Speaker/ Resource person at national, International conferences, Seminars, ROTPs and CMEs. He has been instrumental in organising seminars / Public conferences on different topics as an organising committee member.

Abstract:

Charaka, Sushruta and Vagbhata Samhita-texts are the fundamental trinity for explanation of deep knowledge regarding various aspects of preventing diseases and illustration of various treatments for various disease conditions in 5000BC. Ayurveda explains Ashtanga Ayurveda- eight pillars of different specialities of treatment for different types of ailments. These are kaya chikitsa- medicinal treatment, Bala chikitsa - paediatrics, Graha chikitsa -  Psycho- somatic diseases, Urdhvaanga chikitsa -(Shalakya)- diseases pertaining to ear, nose, throat, mouth, eye, Shalya chikitsa - surgical treatments / surgeries, Danshtra- toxicology, Jara chikitsa - geriatrics and Vrisha chikitsa - science of aphrodisiacs.  Basic texts of Ayurveda elucidate various types of treatments such as Shamana- medicinal treatment, shodhana-Panchakarma-body cleansing treatments along with some specialised treatments such as Kshara sutra treatment, Agnikarma- Heat therapy- cauterization, Jaluka treatment- leech therapy, Vrana chikitsa- wound management and shalya chikitsa – surgeries and fracture management. In this paper various examples of therapies of Ayurveda like Rejuvination, Panchakarma, Pottalli pindasweda,  Agnikarma, Ksharasutra, Ksharkarma, jaloukavacharana, viddha Chikitsa etc. will be presented with their role in prevention and managment of various diseases. Also as probiotic effect of this therapis as well as Seasonal regimen (Ritucharya).

 

  • Probiotics: Applications and Challenges | Nutrition | Animal Nutrition
Location: Prague, Czech Republic
Speaker
Biography:

Maria Kardakova is an expert in the fields of Public Health, Epidemiology, Human Nutrition and Immunology in the UK. Her aim is to increase collaboration between business enterprises and scientific institutions in order to accelerate innovation in food manufacturing and healthcare.

 

Abstract:

Kefir is a fermented milk beverage produced by the action of a complex mixture of microorganisms, including lactic acid bacteria (LAB), yeasts and acetic acid bacteria. According to Rosa et al, 2017, regular consumption of kefir has been associated with improved digestion and lactose tolerance, antibacterial and hypocholesterolemic effects, plasma glucose control, antihypertensive and anti-inflammatory effects, antioxidant, anticarcinogenic and antiallergenic activity and wound healing effects. Kefir contains a wide range of beneficial microorganisms. Kefir has the potential to become a staple item in the dairy category since it is safe, natural, has a low production cost, and can be easily incorporated into the diet. Physiological effects described in the literature support the health-promoting benefits of kefir. In some countries, kefir is a regular option to drink in schools, hospitals, and care establishments. Latest research papers highlight kefir beneficial properties in restoring gut microbiome after the antibiotic treatment, controlling inflammation and increasing the efficiency of immune response as well as having positive effects on the symptoms of constipation. Kefir improves bowel satisfaction scores and accelerates colonic transit which may be a critical point for bedridden patients. However, starting materials, technological process variables (pH level, temperature and duration of fermentation) and flavouring, affect kefir’s final characteristics such as taste, texture, chemical and microbial composition. Kefir health benefits may vary depending on its bacterial content. The future of kefir manufacturing include: A clear evaluation of kefir’s bacterial content; In vivo studies for better understand the mechanisms of action of kefir in oxidative stress, immune modulatory action, anti-inflammatory properties, modulation of gut microbiota and maintenance of gut integrity; further, animal and clinical studies demonstrating the health benefits of kefir consumption with improved study design, sample size and relative study duration; the interaction between dairy industry and scientific institutions can help with further solutions for the standardization of fermented drinks production.

 

 

 

 

Speaker
Biography:

Claudia Gravaghi has 14 years of progressively advancing career as an Academic Researcher in Nutrition, Cancer and Metabolic Diseases. She has worked as Research Fellow to study the effect of omega-3 on mouse models colon rectal cancer and IBD at the Strang Cancer Prevention Centre at the Rockefeller University. She went on to work at Weill Cornell Medical College at the New York Presbyterian Hospital after being awarded a grant in Nutrition and Cancer Prevention by the NIH to investigate the effect of obesity on breast cancer. In the last eight years, she has been relentlessly working as private Clinical Nutritionist creating a dietary regime to improve digestive symptoms especially during chemotherapy in gastrointestinal cancer patients.

 

Abstract:

In the last decade, interactions between human microbiome and tumor have attracted much interest in trying to understand the characteristics of complex microbial communities, as well as their possible mechanisms through which they are involved in cancer prevention, carcinogenesis and anti-cancer therapy. Cancer patients can benefit from different types of therapeutic strategies. However, the toxicities associated with these therapies can cause dysbiosis, colitis and IBS symptoms, affecting the patient's quality of life and the response to therapy. Several studies identify a compositional and functional imbalance in the intestinal microbial community associated with GI mucositis induced by chemotherapy. Furthermore, signs of a previous dysbiosis may also occur due to the effect of gastric tumors on the digestive system, increasing the risk of systemic infections. It is well known that there are several dietary interventions aimed to improve dysbiosis and IBS symptoms. In this contest, a dietary regime containing low glycaemic index foods, high in soluble fibre, adequate in protein, high in omega-3 containing foods (wild fish and low in omega-6 nuts), dairy free, red and cured meat free was effective in reducing or eliminating IBS symptoms, such as diarrhoea/constipation episodes, and bloating in 80% of the patients analysed (n=146, age18-64, 120 women, 26 men). The purpose of this study was to see if the same dietary regime, in combination with the administration of probiotics containing Lactobacillus rhamnosus, applied to a small number of pancreatic cancer patients at the beginning of their first cycle of chemotherapy will improve the common gastrointestinal side effects to prevent weight loss and dysbiosis. Preliminary results (patients n=10, age 40-75 without metastatic tumours) show that all the patients experience only short diarrheal episodes and tiredness in the two days after the chemotherapy but no further digestive symptoms in the following days or weight loss.

 

 

Speaker
Biography:

Kwang-Won Lee has completed his PhD from Iowa State University and postdoctoral studies from  University of Misssouri. He is a Professor of Korea University. He has published more than 33 papers in SCI(E) journals since 2016 and served as Secretary General of Korean Society of Food Science and Technology in 2107.

 

Abstract:

Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial in- flammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard re- action products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-κB in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.

 

Speaker
Biography:

Rekha Bhavnani is a 2nd year nutrition student at London south Bank University. Interested in the health and wellbeing of the population has encouraged her to pursue a career in the field and has a particular interest in probiotics

Abstract:

Over the last decade there is an augmented awareness in the results of pre- and probiotics and its outcome on the microbiome and health and disease. This has stood determined by enhancement in recent discoveries indicating the imperative role of microbiota in common health disorders such as obesity, type II diabetes mellites, irritable bowel syndrome (IBS), Irritable bowel disease (IBD), a variety of cancer, neuroendocrine function, respiratory disorders and many more. These are only some of the common disease in today’s

world.

Established and developing civilisations are making their way to an increase on immune and gut related health problems. Different studies suggest that emerging nutritional strategies may be responsible in promoting health benefits to the consumer by manipulating the gut flora.

These innovative findings in pre and probiotics show promising tools for the nutrition community. These ingredients found in a variety of foods may indicate improvement in gut function and physiology as well as metabolic function

“Live microorganisms which when administered in adequate amounts confer a health benefit on the host”

This article will look into the mechanism of the microbiome, the effects of pre and probiotics and the advantages and disadvantages of administering pre and probiotics on chronic diseases

    

 

 

Speaker
Biography:

Filip Petrović is a Master’s degree student at the University of Rijeka-Department of Biotechnology, studying Biotechnology in Medicine and having previously graduated as Bachelor of Biotechnology and Drug Research. His area of experience is in dietary supplements, having worked for several years in pharmaceutical companies as a Representative. His scientific background is in research of probiotics and prebiotics, aiming at the development of innovative pharmaceutical products.

Abstract:

Introduction: The human microbiome and its probiotic constituents have been the subject of many recent studies, primarily concerning their influence on the human health. Alpha and beta glucans are polysaccharide compounds whose immunomodulatory action had been investigated intensively. Several studies conducted within the last decade have found that these compounds also affect human intestinal flora, especially probiotic bacteria, to which they have a prebiotic effect. Researchers found that fungal polysaccharides improve survival of probiotic bacteria under unfavorable conditions. Moreover, it was found that fungal polysaccharides can induce faster growth of probiotic bacteria, which can lead to faster colonization of the human gastrointestinal system. The purpose of this study is to investigate the growth kinetics of different species of probiotic bacteria from the Lactobacillus genus supplemented with fungal polysaccharides.

Methodology: Investigation of bacterial growth was conducted by measuring the increase of bacterial density in cultures on a HIDEX Sense Multi-Technology Microplate Reader, which allowed 24-hour measurement of optical density while shaking and incubating the cultures at 37°C.

Results: We found that all six of the investigated Lactobacillus species display a very similar response to supplementation of growth media with fungal polysaccharides. Supplementation resulted in significant reduction of LAG phase in all six species compared to control samples, combined with increased growth rate (shorter duplication time) in the majority of samples, compared to control. The effect was found to be dose-dependent, culminating at 1% w/w extract. The effect was confirmed using high-purity yeast beta-glucans, which were shown to be effective even at much lower concentrations.

Conclusions: In this study we demonstrated that fungal polysaccharides, namely fungal beta-glucans, induce a significant change in the growth kinetics of different Lactobacillus species– reduction of LAG phase and increase of growth rate. This strong effect can be of great significance in development of future therapies for digestive disorders or development of new pharmaceuticals.

 

Speaker
Biography:

Rob Davis is a graduate of the Pennsylvania State University, and a Certified Lean Master, with more than 30 years of manufacturing operations experience, the majority of which is in food manufacturing. Rob has done extensive work in process improvements in canning and pet food operations. He has developed unique Operations Excellence models which are used in many U.S. manufacturing locations. He has also led to the rescue of more than 50 homeless animals.

Abstract:

The Global Pet Market is fast-growing, in excess of 100 Billion USD, and highly-competitive.  Pet ownership is on the increase, as is the number of multi-pet households.  Pet ownership is also rising in child-less households, including singles, newlyweds, and seniors.  This dynamic is creating more pressure in the humanization of pets, as they frequently act as a substitute for human companionship.  Problem Statement:  As the humanization of pets continues, pet owners take the approach of “What is good for me is good for my pet”, regardless of true impact.  This can result in nutritional challenges, as pet requirements differ from human requirements.  The growing trend in Human probiotic consumption has led to the desire by pet owners to share the same consumption benefits with their pets.  In the highly-competitive Pet Sector, this has resulted in pressure to provide pet food containing probiotics.  Adding probiotics to long-established pet food manufacturing processes has created operational challenges.

Methodology:  When it became legal via patent expiration in the U.S. to apply probiotics in pet food, extensive product development and testing was necessary.  The challenges ranged from ingredient costs to ingredient handling to application points to probiotic survivability. 

Findings:  While operational success has been attained in probiotic applications, the desire for this type of product continues to present challenges that may or may not offset the true dietary benefits.

Conclusions:  Additional testing is recommended to determine the true cost-benefit relationship in pet food, which will ultimately determine future marketing and pricing strategies. 

 

Asa Saligupta

Inter Trading Manager of Probiotic and Herbal Co., Ltd., Thailand

Title: Immune system dysfunctions, the cause of incurable
Speaker
Biography:

Asa Saligupta is working as a Inter Trading Manager of Probiotic and Herbal Co., Ltd. He studied high school in England, completed his Bachelor degree in Bangkok and got his Master degree from Missouri, USA. He was the Past President of Rotary club, committee of Tourism Association, committee of Thai Print Association, etc. He worked at the Kansas City Enquirer, NEXT Advertising Agency, owner of car dealership, owner of hotel, owner of restaurant, co-partner of travel agency, lecturer at Rajabhat University & Chulalongkorn University, etc.

Abstract:

You may be surprised to know that immune system dysfunctionality links too many symptoms and can be said that it covers all of the incurable diseases such as: Low level of immunity within the body is susceptible to cancer, liver disease, tuberculosis, AIDs of HIV and infections from bacteria and germ, etc.; if the immune system is too sensitive, it could lead to allergy, asthma, urticaria and sinusitis; if the body’s immune system does not work right, it could lead to rheumatism, SLE, psoriasis, diabetes with itchiness and digestive system inflammation. So, it’s hard to believe that our own immune system, if not working correctly, could cause so many damages to our body. Our research found that the lack of balance in our body, especially amongst modern people, came from addiction of chemical medicines. Once digested, it destroys all the bacteria in the microbiota group leaving the body unbalanced, without helper, without coordinator. The white blood cell acts abnormally hence, the illness to the body. Today, you can choose your healing method by using microbes to help maintain balance to your body and contain bacteria so that microbiota returns to work. The body will be balanced again and the immune system back to normalcy.